Name: 2',3'-cGAMP Sodium Salt
Brand: Selleck Chemicals
SKU: S7904
Availability: InStock
Rating: 5 (5 reviews)

Jump to

Quality Control

Batch: Purity: 99.83%

99.83

Products Often Used Together with 2',3'-cGAMP Sodium Salt

Vadimezan (DMXAA)

It and Vadimezan (DMXAA) are both capable of re-educating M2 cells towards an M1 phenotype.

BV6

It, together with BV6, exerts antitumor effects on PC cells.

3',3'-cGAMP

Both this compound and 3',3'-cGAMP equally mature human monocyte-derived DCs, upregulating CD40/CD80/CD86/HLA-DR markers.

diABZI STING agonist-1 (tautomerism)

It and diABZI STING agonist demonstrate the most potent, broad-spectrum antiviral function.

Related Targets	PD-1/PD-L1 CXCR AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor
Other STING Inhibitors	diABZI STING agonist-1 (tautomerism) H-151 C-176 CCCP STING inhibitor C-178 SN-011 MSA-2 C-171 G10 (STING agonist-1) SN-001

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
293T	Function assay		30 mins	Activation of recombinant human STING haplotype R71H/G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.02 μM.	31715099
293T	Function assay		30 mins	Activation of recombinant human wild-type STING expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.02 μM.	31715099
293T	Function assay		30 mins	Activation of recombinant human STING haplotype G230A/R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.04 μM.	31715099
293T	Function assay		30 mins	Activation of recombinant human STING haplotype R293Q mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.05 μM.	31715099
293T	Function assay		30 mins	Activation of recombinant human STING haplotype R232H mutant expressed in 293T cells measured after 30 mins in presence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 0.07 μM.	31715099
293T	Function assay		7 hrs	Activation of recombinant human wild-type STING expressed in 293T cells incubated for 7 hrs in absence of digitonin A by bright Glo-luciferase reporter gene assay, EC50 = 13.7 μM.	31715099
THP1	Function assay		20 hrs	Agonist activity at STING in human THP1 cells assessed as stimulation of IRF3 pathway measured after 20 hrs by luciferase reporter gene assay, EC50 = 38.6 μM.	31820985
PBMC	Function assay	69.6 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in CXCL10 mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	31820985
PBMC	Function assay	1.39 to 139 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in IFNbeta release at 1.39 to 139 uM measured after 4 hrs by ELISA	31820985
PBMC	Function assay	69.6 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in IFNbeta mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	31820985
PBMC	Function assay	69.6 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in IL6 mRNA level at 69.6 uM measured after 4 hrs by qRT-PCR analysis	31820985
PBMC	Function assay	139 uM	4 hrs	Agonist activity at STING in human PBMC cells assessed as increase in IL6 production at 139 uM measured after 4 hrs by ELISA	31820985
B16-OVA	Antitumor assay			Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as tumour regression in injected flank at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	31500996
B16-OVA	Antitumor assay			Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as tumour regression in contralateral flank at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	31500996
B16-OVA	Antitumor assay			Antitumor activity against mouse B16-OVA cells implanted in mouse assessed as higher number of mouse cured of tumors at 10 ug administered intratumorally on day 6, 9 and 12 post implantation	31500996
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (139.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	718.37	Formula	C₂₀H₂₂N₁₀Na₂O₁₃P₂	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	2734858-36-5	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

Targets/IC₅₀/Ki	STING (Cell-free assay) 3.79 nM(Kd)
In vitro	2',3'-cGAMP is an endogenous second messenger produced by mammalian cells. 2',3'-cGAMP is a high affinity ligand for STING. 2',3'-cGAMP is a potent inducer of type-I interferons. 2',3'-cGAMP binding induces conformational changes of STING.
References	[1] https://pubmed.ncbi.nlm.nih.gov/23747010/ [2] https://pubmed.ncbi.nlm.nih.gov/30728498/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

2',3'-cGAMP Sodium Salt Sting Agonist

Chemical Structure

Molecular Weight: 718.37